Physician profile
Roger E Cagle
NPI 1134282999
$2,364.67
in general payments reported to CMS, 2019-2025
24 companies · $42.33 in 2025
The $42.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $699 · 2021: $766 · 2022: $259 · 2024: $26.59 · 2025: $42.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $297.27 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $296.90 | 2019-2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.03 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $167.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.63 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $144.03 | 2019-2020 | |
| Pfizer INC. | $105.62 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.70 | 2019-2022 | |
| Allergan, INC. | $74.93 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $64.94 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $53.94 | 2020-2021 | |
| Daiichi Sankyo INC. | $40.80 | 2019 | |
| Abbott Laboratories | $38.69 | 2022 | |
| Lundbeck LLC | $27.90 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.59 | 2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $16.35 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.65 | 2021 | |
| Novo Nordisk INC | $15.01 | 2020 | |
| Lilly USA, LLC | $13.40 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.36 | 2021 | |
| Upsher-Smith Laboratories LLC | $12.30 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.06 | 2019 | |
| Mylan Specialty L.P. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.